70th Heidelberg Grand Rounds - Immunotherapy



This year, the NCT Heidelberg is again organizing several Heidelberg Grand Rounds. The format is aimed at clinicians as well as  researchers and provides a platform for effective scientific exchange. Recognized experts will present the latest clinical and research results in selected oncological fields.

We look forward to welcoming you to the virtual conference room.  


Prof. Dr. Dirk Jäger


Participation is free of charge. 

Thanks to our sponsors: 

Bristol-Myers Squibb GmbH & Co. KGaA - 2.500 €
Takeda Pharma Vertrieb GmbH & Co. KG
- 1.250 €


The NCT Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and German Cancer Aid (DKH).

Organizer: Heidelberg University Hospital (UKHD)
Event language: English

Note: If the registration form does not open, please switch browsers once and try again.

    • 16:00 16:15
      Welcome 15m
      Speakers: Prof. Dirk Jäger (National Center for Tumor Diseases (NCT) Heidelberg / Heidelberg University Hospital (UKHD)), Prof. Peter Krammer
    • 16:15 16:45
      CAR-T-Cell therapy in B-cell malignancies 30m
      Speaker: Dr Uta Höpken (MDC Berlin )
    • 16:45 17:15
      Flanking solid tumors via immune-mediated disruption of desmoplastic stroma 30m

      Ellen Puré, Ph.D. is Grace Lansing Lambert Professor and Chair of Biomedical Sciences and Professor of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania. Dr. Puré received her Baccalaureate degree from Washington University in St. Louis, and her doctorate at the University of Texas-Southwestern Medical School. She trained as a Damon Runyon-Walter Winchell Postdoctoral Fellow and Leukemia Society Special Fellow and then joined the Faculty at the Rockefeller University. In 1992 Dr. Puré moved to Philadelphia where she was on the Faculty of the Wistar Institute until moving to the University of Pennsylvania in 2013. Dr. Puré is an Associate Director of the Cancer Research Institute and serves on the editorial boards of the Journal of Clinical Investigation and Matrix Biology and is a Founding Senior Editor of Cancer Immunology Research. Dr. Puré’s research focuses on the cellular and molecular basis of inflammation and fibrosis. She studies basic mechanisms involved in these processes and the contribution of these processes to fibrotic diseases and cancer. Her laboratory has made seminal contributions to our understanding of the roles of stromal cells and extracellular matrix remodeling in tissue fibrosis and in cancer risk, initiation, progression and metastasis. Her lab is developing novel therapeutic approaches to target stroma to treat fibrosis and cancer.
      In 2019, Dr. Puré was named a Fellow in the American Association for the Advancement of Science (AAAS).

      Speaker: Dr Ellen Puré (University of Pennsylvania)
    • 17:15 17:45
      A different kind of checkpoint - The annexin checkpoint system regulates anti-tumor immune responses 30m
      Speaker: Dr Heiko Weyd (German Cancer Research Center (DKFZ) Heidelberg)
    • 17:45 18:15
      tbd 30m
      Speaker: Prof. Gerald Willimsky (Hospital Charité Berlin / German Cancer Research Center (DKFZ) Heidelberg)
    • 18:15 18:45
      tbd 30m

      Pablo Umaña is Head of Cancer Immunotherapy Discovery. He obtained his PhD in Chemical Engineering and Biology from the California Institute of Technology in 1998 carrying out experimental work at ETH-Zurich. In 2001 co-founded GlycArt Biotechnology AG in Zurich-Switzerland, a company spinning out of research carried out at the ETH-Zurich, and headed its research since the company’s foundation. To date he continues to lead research at the Roche Innovation Center Zurich as part of the Pharma Research and Early Development (pRED) organization within Roche, after GlycArt was acquired by Hoffmann La Roche AG in 2005.

      He led the team that discovered and initially developed GAZYVA, a novel Type II CD20 antibody for the treatment of B-cell malignancies. GAZYVA was approved on Nov 1, 2013 by FDA for 1L CLL and is the first ever medicine approved by the FDA under the Breakthrough Therapy regime. He has also led the research for the generation and initial development of Roche-pRED’s tumor-targeted-T-cell bispecific, -immunocytokine and -immunomodulator platforms and drug candidates in the field of cancer immunotherapy.

      Speaker: Dr Pablo Umaña (Roche Glycart AG)
    • 18:45 19:00
      Closing remarks 15m
      Speaker: Prof. Dirk Jäger (National Center for Tumor Diseases (NCT) Heidelberg / Heidelberg University Hospital (UKHD))